(Q43232067)

16 November 2017

title

Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema (English)

1 reference

16 November 2017

1 reference

Miltiadis K. Tsilimbaris

1

1 reference

16 November 2017

author name string

Vassilios Pandeleondidis

2

1 reference

16 November 2017

Theoni Panagiototglou

3

1 reference

16 November 2017

Vassiliki Arvanitaki

4

1 reference

16 November 2017

Sofia Fragiskou

5

1 reference

16 November 2017

Maria Eleftheriadou

6

1 reference

16 November 2017

Chrysanthi Tsika

7

1 reference

16 November 2017

Theokliti Papadaki

8

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Seminars in Ophthalmology

16 November 2017

published in

1 reference

16 November 2017

volume

24

1 reference

16 November 2017

issue

6

1 reference

16 November 2017

page(s)

225-230

1 reference

Diabetic macular edema: pathogenesis and treatment

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Etiology and treatment of macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal triamcinolone for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal steroids for macular edema: the past, the present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Triamcinolone acetonide in ocular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Vascular endothelial growth factor and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

The role of bevacizumab as first-line therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820530903389775

10.3109/08820530903389775

21 January 2018

Identifiers

DOI

1 reference

release_kgz5c4sl7jflvgp2zmwcu77niu

16 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kgz5c4sl7jflvgp2zmwcu77niu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference